Shares of Chinese biotechnology company WuXi AppTec (02359) surged 6.26% on Monday, despite the company reporting a 17% decline in its third-quarter net profit and a 1.96% drop in revenue. The rally came as a surprise, given the weaker-than-expected earnings performance.
However, analysts at Jefferies remained optimistic about the company's prospects, maintaining a "buy" rating on the stock. Jefferies stated that WuXi AppTec's Q3 results were in line with market expectations and consensus. Furthermore, the firm highlighted the company's accelerating growth in total backlog, indicating stronger revenue momentum ahead.
The positive sentiment from Jefferies and the prospects of robust revenue growth in the future appear to have outweighed the concerns over the Q3 earnings dip. Investors seem to be betting on WuXi AppTec's ability to capitalize on its growing backlog and drive future growth, driving the stock to its highest level since October 10th.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。